Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1: GU tumours, non-prostate

1450MO - Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC

Date

11 Sep 2022

Session

Mini Oral session 1: GU tumours, non-prostate

Topics

Clinical Research;  Immunotherapy

Tumour Site

Renal Cell Cancer

Presenters

Marc-Oliver Grimm

Citation

Annals of Oncology (2022) 33 (suppl_7): S660-S680. 10.1016/annonc/annonc1072

Authors

M. Grimm1, E. Esteban Gonzalez2, P. Barthelemy3, M. Schmidinger4, J. Busch5, B. Perez Valderrama6, N. Charnley7, M. Schmitz8, U. Schumacher9, G. Baretton10, I. Duran Martinez11, G.A. De Velasco Oria12, F. Priou13, J.P. Maroto Rey14, L. Albiges15

Author affiliations

  • 1 Department Of Urology, Jena University Hospital, Friedrich-Schiller University Jena, 07747 - Jena/DE
  • 2 Department Of Medical Oncology, Hospital Universitario Central de Asturias, 33006 - Oviedo/ES
  • 3 Department Of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 - Strasbourg/FR
  • 4 Department Of Urology, Medical University of Vienna, 1090 - Vienna/AT
  • 5 Department Of Urology, University Hospital Charité Berlin, Berlin/DE
  • 6 Department Of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 - Seville/ES
  • 7 Department Of Oncology, Royal Preston Hospital, PR2 9HT - Preston/GB
  • 8 Institute Of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, 01307 - Dresden/DE
  • 9 Center For Clinical Studies, Jena University Hospital, Friedrich-Schiller University Jena, Jena/DE
  • 10 Institute Of Pathology, University Hospital Carl Gustav Carus, TU Dresden, Dresden/DE
  • 11 Dept. Despacho 271, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39008 - Santander/ES
  • 12 Department Of Oncology, Hospital 12 de Octubre, 28041 - Madrid/ES
  • 13 85, CHD Vendee-Hopital Les Oudairies, 85925 - La Roche-sur-Yon/FR
  • 14 Department Of Medical Oncology, Hospital de la Santa Creu I Sant Pau, 08041 - Barcelona/ES
  • 15 Department Of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Sud, 94805 - Villejuif/FR

Resources

This content is available to ESMO members and event participants.

Abstract 1450MO

Background

The combination of nivolumab 3 mg/kg + ipilimumab 1 mg/kg (nivo+ipi) is an approved 1st line (1L) therapy for patients with metastatic renal cell carcinoma (mRCC) and intermediate / poor risk. TITAN-RCC investigated a response-based approach with nivo induction and nivo+ipi boost in non-responders. We report final study results for 1L and 2L (after TKI) patients.

Methods

From OCT 2016 to DEC 2018 207 patients with intermediate/poor risk mRCC started nivo induction (Q2W, 240 mg). Patients with early progressive disease (PD, week 8) or non-responders at week 16 (stable disease [SD]/PD) received 2-4 doses nivo+ipi. Responders to nivo induction (complete/partial response [CR/PR]) continued with nivo maintenance but could receive nivo+ipi for later PD. The primary endpoint was confirmed objective response rate (ORR) per RECIST in 1L and 2L. Secondary endpoints included efficacy of nivo induction, response to boost, progression free (PFS) and overall survival (OS), and safety.

Results

Of the 207 patients, 109 were 1L and 98 2L. Median age was 65 yr, 71 % of patients had intermediate and 25 % poor risk. Confirmed response to nivo induction was 28 % in 1L and 18 % in 2L. After 33.6 months from last patient first treatment and 15.9 months median follow-up, ORR for nivo ± nivo+ipi was 36 % in 1L (significant >25 %, p<0.05) and 32 % in 2L. Irrespective of time point, 44% (1L) and 53% (2L) of patients receiving boosts for PD upon nivo improved in best response. PFS was 6.3 months (95 % CI 3.7-10.1) in 1L and 3.7 months (95 % CI 1.8-4.5) in 2L. OS was 32.0 months (95 % CI 22.9-39.4) in 1L and 25.9 months (95 % CI 17.8-33.7) in 2L. No new safety signals emerged. Table: 1450MO

Response to nivo+ipi boost

1L 1L 1L 2L 2L 2L
Initial effect SD (n=21) PD (n=28) all (n=17) SD (n=17) PD (n=42) all (n=11)
Start of first boost cycle week 8/16 week 8/16 >week 16 (late boost) week 8/16 week 8/16 >week 16 (late boost)
CR, n (%) 1 (5) - - - 3 (7) -
PR, n (%) 4 (19) 3 (11) 3 (18) - 7 (17) 2 (18)
SD, n (%) 13 (62) 8 (29) 6 (35) 12 (71) 12 (29) 4 (36)
PD, n (%) 3 (14) 17 (61) 6 (35) 4 (24) 17 (40) 4 (36)
Not evaluable, n (%) - - 2 (12) 1 (6) 3 (7) 1 (9)

Conclusions

Nivo+ipi boosts improve outcomes compared to nivo monotherapy. Responses were also observed after progression during nivo maintenance suggesting a potential role as rescue strategy. However, overall efficacy of our tailored approach appears to be inferior compared to upfront nivo+ipi treatment.

Clinical trial identification

EudraCT: 2016-002307-26, NCT02917772.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien-gGmbH.

Funding

Bristol Myers Squibb.

Disclosure

M. Grimm: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Bristol Myers Squibb, Ipsen Pharma, Merck Serono, MSD, Pfizer, EUSA, Janssen, Oncinfo, Deutsche Gesellschaft für Urologie; Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, EUSA Pharma, Ipsen Pharma, Merck Serono, MSD, Pfizer, Roche, Eisai, Takeda, Astellas, Ingress Health, Janssen Cilag; Financial Interests, Personal and Institutional, Invited Speaker: Bristol Myes Squibb; Financial Interests, Institutional, Invited Speaker: Intuitive Surgical. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen. M. Schmidinger: Financial Interests, Personal, Advisory Board, advisory boards or lectures: BMS, MSD, Merck, Ipsen; Financial Interests, Personal, Invited Speaker: EUSA, Janssen; Financial Interests, Personal, Advisory Board: Alkermes, Exelixis; Financial Interests, Personal, Advisory Board, Advisory board or lectures: Eisai; Financial Interests, Institutional, Research Grant, Research grant for retropsective study: Ipsen. J. Busch: Financial Interests, Personal, Invited Speaker: BMS, Merck, Ipsen, Pfizer, Janssen, Astellas; Financial Interests, Personal, Advisory Board: MSD, Merck, Ipsen, BARD, AstraZeneca. B. Perez Valderrama: Financial Interests, Personal, Advisory Board: Pfizer, Astellas Pharma, Bristol Myers Squibb, Ipsen, EUSA Pharma, Sanofi-Aventis, Merck, MSD, AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Roche, Bayer, EUSA Pharma, MSD, Merck, Pfizer, Janssen, Astellas Pharma. N. Charnley: Financial Interests, Institutional, Funding: BMS; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Funding: Ipsen, EUSA. G. Baretton: Financial Interests, Personal, Advisory Role: BMS, MSD, AstraZeneca, Roche, Novartis; Financial Interests, Institutional, Funding: BMS, MSD; Financial Interests, Personal, Other, Honoria: Pfizer, Roche, MSD, BMS, AstraZeneca. I. Duran Martinez: Financial Interests, Personal, Advisory Board, I have served as an advisor for this company in the last two years: Roche Genentech, MSD, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker, I have participated in different compensated educational activities sponsored by Jansen over the last two years: Jansen; Financial Interests, Personal, Invited Speaker, I have participated in different compensated educational activities sponsored by Pfizer over the last two years: Pfizer; Financial Interests, Personal, Advisory Board, I have collaborated as an advisor in different occasions over the last two years: ipsen; Financial Interests, Personal, Invited Speaker, I have participated in different compensated educational activities sponsored by this company over the last two years: IPSEN, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, I have collaborated as an advisor for this company in the last two year: Merck; Financial Interests, Personal, Advisory Board, I have participated in different compensated advisory boards over the last two years: Astellas; Financial Interests, Personal, Advisory Board, I have collaborated as an advisor for this company over the last two years: Immunomedics, Inc.; Financial Interests, Personal, Invited Speaker, I have participated in educational activities sponsored by this company in the last two years: EUSA Pharma, MSD; Financial Interests, Personal, Invited Speaker, I have participated in educational activities sponsored by Novartis in the last 2 years: Novartis; Financial Interests, Personal, Invited Speaker, I have participated in compensated educational activities for this company in the last two years: Astellas; Financial Interests, Personal and Institutional, Research Grant, Roche has funded research in my institution to projects under my coordination: Roche Genentech; Financial Interests, Personal, Invited Speaker, I serve as a member of a SC for a trial sponsored by this company: Immunomedics, Inc.; Financial Interests, Personal and Institutional, Research Grant, AZ has funded research conducted in my institution related to a project where I am the PI: AstraZeneca; Non-Financial Interests, Leadership Role, I am the president of an independent cooperative group of GU Oncologist from the north of Spain: GO NORTE; Non-Financial Interests, Invited Speaker, I belong as a external advisor to the board of directors of the Spanish Association of cancer research since 2021: ASEICA. G.A. De Velasco Oria: Financial Interests, Personal, Advisory Board: Pfizer, astellas, BMS, MSD, Ipsen, Bayer, Eusa P., Merck; Financial Interests, Personal, Invited Speaker: Pfizer, astellas, BMS, MSD, Roche, Ipsen, Merck; Financial Interests, Institutional, Research Grant: Roche. F. Priou: Financial Interests, Personal, Advisory Board: MSD, AstraZeneca. J.P. Maroto Rey: Non-Financial Interests, Advisory Role: Bayer, MSD, Astellas, Merck. L. Albiges: Financial Interests, Institutional, Other, Consulting: Astellas, AstraZeneca, BMS, Eisai, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer; Non-Financial Interests, Principal Investigator: Pfizer, BMS, Ipsen, AVEO, AstraZeneca, MSD; Non-Financial Interests, Other, Clinical trial steering committee: Roche, Exelixis; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Other, Medical Steering Committee: Kidney Cancer Association; Non-Financial Interests, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology (EAU); Non-Financial Interests, Other, Member of the Kidney Cancer Research Summit scientific committee 2021: Kidney Can; Other, Scientific Committee: BMS France. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.